logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Anifrolumab for moderately to severly active, autoantibody-positive systemic lupus erythematosus

< Back

Anifrolumab for moderately to severly active, autoantibody-positive systemic lupus erythematosus

Drugs

Immunology and Allergy

April 2020


Anifrolumab is currently in clinical development for the treatment of moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the body’s immune system attacks its own tissues and organs. Patients will often have periods where their symptoms flare-up and periods where their symptoms settle down. The exact causes of SLE are unknown but are believed to be due to a combination of genetic, environmental and hormonal factors. Recent evidence suggests that activation of the type I interferon (IFN) system which is a group of proteins involved in the regulation of the activity of the immune system may play a central role in development of SLE.

Anifrolumab is a drug designed to specifically block type I IFN signalling by binding to part of the type I IFN receptor and therefore preventing activity of all IFNs that are involved in the inflammatory pathway. If licensed, anifrolumab will offer an add-on treatment option for patients with moderately to severely active SLE.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts